67 completed, 8 terminated, 5 unknown, 1 not yet recruiting. 28 Phase 3, 20 Phase 1, 17 Phase 2, 13 Phase 4, 1 Not applicable.
Follow rotigotine: new trials by email Literature Review of rotigotine trials Research Report on rotigotine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adhesion and Safety of Rotigexole Compared to Neupro® Rotigexole 8 mg, Neupro ® 8 mg - Idiopathic Parkinson Disease | Not applicable | Not yet recruiting | Eva Pharma | 40 | 2025-09-01 | 2025-08-07 |
| A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease Rotigotine 4Mg/24Hrs Patch, Placebo - Alzheimer Disease | Phase 3 | Recruiting | I.R.C.C.S. Fondazione Santa Lucia | 348 | 2023-12-01 | 2025-01-22 |
| Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder Rotigotine Transdermal System [Neupro], Placebo - Substance-Related Disorders | Phase 2 | Completed | Virginia Commonwealth University | 50 | 2023-09-11 | 2026-08-31 |
| Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease Rotigotine 8Mg/24Hrs Patch - Parkinson Disease | Phase 2 | Completed | SocraTec R&D GmbH | 38 | 2021-08-23 | 2024-05-01 |
| The Practical Effect of Neupro Neupro - Parkinson's Disease | Unknown | Peking University Third Hospital | 3000 | 2021-07-01 | 2021-07-12 | |
| Dopaminergic Therapy for Frontotemporal Dementia Patients Rotigotine 4Mg/24Hrs Patch, Rotigotine 6Mg/24Hrs Patch, Placebo - Frontotemporal Dementia, Dementia | Phase 2 | Completed | I.R.C.C.S. Fondazione Santa Lucia | 75 | 2021-06-03 | 2024-10-22 |
| A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection), Neupro 4 mg / 24 Hr. Transdermal Patch - Parkinson Disease | Phase 1 | Completed | Luye Pharma Group Ltd. | 56 | 2020-06-02 | 2020-10-14 |
| A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome Rotigotine 1 mg/24 h, Rotigotine 2 mg/24 h, Rotigotine 3 mg/24 h - Restless Legs Syndrome | Phase 3 | Terminated | UCB Biopharma SRL | 10 | 2019-12-03 | 2023-10-30 |
| An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine. Rotigotine TTS (Test), Neupro (Reference) - Parkinson Disease | Phase 1 | Terminated | Sandoz | 31 | 2019-12-03 | 2020-11-09 |
| A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause Rotigotine 1 milligram/24 hours, Rotigotine 2 milligram/24 hours, Placebo - Restless Legs Syndrome | Phase 3 | Terminated | UCB Biopharma SRL | 23 | 2018-12-20 | 2023-10-26 |
| A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro LY03003, Neupro 4Mg/24Hr Transdermal Patch - Parkinson Disease | Phase 1 | Completed | Luye Pharma Group Ltd. | 40 | 2018-11-09 | 2021-04-02 |
| Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease LY03003 - Parkinson Disease | Phase 1 | Completed | Luye Pharma Group Ltd. | 24 | 2018-05-15 | 2018-11-08 |
| A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease LY03003 ( Rotigotine, extended-release microspheres), Placebo, extended-release microspheres - Parkinson Disease | Phase 1 | Completed | Luye Pharma Group Ltd. | 30 | 2017-10-10 | 2020-09-22 |
| Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Kinesia-ONE™, Kinesia-360™, Rotigotine - Parkinson´s Disease | Phase 4 | Completed | UCB Biopharma S.P.R.L. | 40 | 2017-03-16 | 2019-02-19 |
| Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Rotigotine, Placebo - Nocturnal Hypokinesia | Phase 4 | Unknown | Chulalongkorn University | 40 | 2016-09-01 | 2017-03-31 |
| Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment rotigotine transdermal patch, placebo - Anxiety Disorders, Parkinson Disease | Phase 4 | Terminated | Johns Hopkins University | 4 | 2016-08-01 | 2020-03-31 |
| Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease Rotigotine transdermal patch, Placebo - Alzheimer Disease | Phase 2 | Completed | I.R.C.C.S. Fondazione Santa Lucia | 94 | 2016-06-01 | 2018-12-17 |
| Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease ROTIGOTINE - Parkinson's Disease | Phase 1 | Completed | Luye Pharma Group Ltd. | 28 | 2016-05-01 | 2016-12-05 |
| Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model Neupro® transdermal patch/placebo - Post-op Pain | Phase 2 | Unknown | East Carolina University | 50 | 2015-11-01 | 2015-08-07 |
| A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease Rotigotine (Test product PR 2.3.1), Rotigotine (Reference product PR 2.1.1) - Parkinson's Disease | Phase 1 | Completed | UCB BIOSCIENCES GmbH | 57 | 2014-09-01 | 2015-11-02 |
Showing 20 of 82. Sign in to see all of them.
Parkinson Disease (43) · Restless Legs Syndrome (16) · Alzheimer Disease (2) · Lethargy (2) · Neurologic Manifestations (2) · Anxiety Disorders (1) · Aphasia (1) · Aphasia, Primary Progressive (1) · Asthenia (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Chronic Pain (1) · Communication Disorders (1) · Dementia (1)
UCB Pharma (35) · UCB BIOSCIENCES GmbH (9) · Luye Pharma Group Ltd. (7) · Otsuka Pharmaceutical Co., Ltd. (5) · I.R.C.C.S. Fondazione Santa Lucia (3) · UCB BIOSCIENCES, Inc. (2) · UCB Biopharma SRL (2) · Azienda Ospedaliera Cardinale G. Panico (1) · Chulalongkorn University (1) · East Carolina University (1) · Eva Pharma (1) · Inflamax Research Incorporated (1) · John Winkelman, MD, PhD (1) · Johns Hopkins University (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (32) · Germany (27) · Italy (12) · Austria (9) · Spain (8) · United Kingdom (8) · France (6) · Hungary (6) · Poland (6) · South Africa (6) · Australia (5) · China (5) · Finland (5) · Japan (4) · New Zealand (4)
Kyoji Imaoka, Mr (3) · Alessandro Martorana, MD, PhD (2) · Ahad Sabet, MD (1) · Albert Arias, MD (1) · Ali S Shalash, Dr. (1) · Anna Castrioto, MD (1) · Giacomo Koch, MD (1) · Giacomo Koch, MD, PhD (1) · Giancarlo Logroscino, Prof (1) · Giuseppe Frazzitta, MD (1) · Gregory Pontone, MD (1) · Hatem S Mohammed, Dr. (1) · James M Bjork, PhD (1)
PMID 24006953, PMID 26446245, PMID 18515185, PMID 18650802, PMID 18753003, PMID 20535621, PMID 20629075, PMID 20813583, PMID 20920156, PMID 21080009, PMID 21322021, PMID 21705273, PMID 21790503, PMID 21831297, PMID 22326237, PMID 22401642, PMID 23009552, PMID 23103551, PMID 23256574, PMID 23508526, PMID 23668924, PMID 24246378, PMID 24457253, PMID 24602411, PMID 24859851, PMID 25309431, PMID 25772231, PMID 25773763, PMID 25791613, PMID 25846031, PMID 25879416, PMID 26095948, PMID 26569149, PMID 26882318, PMID 27267880, PMID 27322571, PMID 28366342, PMID 28827011, PMID 29461870, PMID 30098648, PMID 32667654, PMID 40809903
2004 (4), 2005 (2), 2014 (2), K23AG044441 (1), U01DA057846 (1)